Alexion Pharmaceuticals, Inc.

This phase 2 trial tests whether adding ALXN2420 (a growth hormone blocker) to standard acromegaly treatment can lower IGF-1 levels more than placebo. About 60 adults with acromegaly who are already on a stable dose of somatostatin analogs will receive either ALXN2420 or placebo …

This study tests a single dose of ravulizumab given before heart surgery to see if it can prevent kidney damage and serious kidney problems in people with chronic kidney disease. About 736 adults will take part. The goal is to reduce the risk of major kidney events within 90 days…

This study tested an intravenous antiplatelet drug called PRT060128 in 70 people having a severe heart attack (STEMI). The goal was to see if giving the drug before emergency artery-opening treatment improved blood flow and was safe. The trial was terminated early, so the full re…

This Phase 2 study tested the drug ravulizumab (Ultomiris) in 123 adults with lupus nephritis or IgA nephropathy, two conditions that cause kidney inflammation. Participants received either ravulizumab or a placebo alongside standard care. The study aimed to see if the drug could…

This study tested a drug called bertilimumab in 32 adults with moderate to severe ulcerative colitis. The goal was to see if it could reduce disease activity compared to a placebo. The trial was terminated early, so results are limited and no clear benefit was established.

This study tested a drug called ALXN2050 in people with kidney inflammation caused by lupus (lupus nephritis) or IgA nephropathy. The goal was to see if it could reduce protein in the urine, a sign of kidney damage. About 100 adults were planned to take the drug or a placebo alon…

This Phase 2 study tested an oral drug called danicopan in 365 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. Participants took different doses of danicopan or a placebo for up to 104 weeks to see if it could slow…